GET DAILY SIGNALSAlector (ALEC) Posts Q3 Profit on One-Time Collaboration Revenue
Key Takeaways
- Alector, Inc. (ALEC) reported third quarter 2026 results, for the period ended September 30, 2026, on November 5, 2026.
- Collaboration revenue jumped to $162.9 million, up from $3.3 million a year earlier, driven by a one-time recognition of deferred revenue after GSK terminated its collaboration.
- Net income swung to $124.6 million, or $1.11 per share, versus a net loss of $34.7 million, or $0.34 per share, in the prior-year quarter.
- Research and development (R&D) expenses were $30.0 million, while general and administrative (G&A) expenses were $9.0 million.
- Cash, cash equivalents, and investments totaled $138.7 million at quarter-end, excluding a $100 million Genentech upfront payment and roughly $75 million in gross proceeds from an October stock offering.
- Management expects its cash position to fund operations into the second half of 2029.
Why the Quarter Matters
Alector is a clinical-stage biotechnology company focused on immuno-neurology, developing therapies to counteract neurodegeneration. Its third quarter 2026 report arrives at a pivotal moment: the company recently struck a global licensing deal with Genentech, a member of the Roche Group, for its AL050 program, and simultaneously absorbed the termination of its collaboration with GSK. For investors, the quarter's headline figures are less about recurring operations and more about the company's transformed balance sheet, extended cash runway, and newly streamlined pipeline. Understanding how much of the reported profit is one-time in nature versus a sustainable shift is central to interpreting the results. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Alector reported collaboration revenue of $162.9 million for the third quarter of 2026, compared with $3.3 million in the same period of 2025. The sharp increase primarily reflected the recognition of remaining deferred revenue under its Collaboration and License Agreement with GSK, following GSK's July 2026 termination notice and the extinguishment of Alector's remaining performance obligations.
The company posted net income of $124.6 million, or $1.11 per share, versus a net loss of $34.7 million, or $0.34 per share, a year earlier. This dramatically exceeded the consensus estimate of a loss of $0.23 per share on revenue of roughly $2.38 million, though the outperformance was driven by non-recurring accounting items rather than operating strength.
On the expense side, R&D costs were $30.0 million, up modestly from $29.4 million, reflecting option and license fees partially offset by lower latozinemab and nivisnebart program costs and personnel reductions. G&A expenses declined to $9.0 million from $11.5 million. Alector ended the quarter with $138.7 million in cash, cash equivalents, and investments, a figure that excludes the $100 million Genentech upfront payment and the net proceeds of its October 2026 underwritten offering of 36.6 million shares priced at $2.05 per share.
Market Reaction and Investor Sentiment
Alector's stock entered the report following a dramatic October rally, when shares surged on news that Roche's Genentech would license the AL050 program in a deal worth up to roughly $1.27 billion including the upfront payment and milestone potential. That run-up set a high bar heading into earnings. On the release day, shares pulled back in regular trading before recovering modestly in after-hours activity, reflecting profit-taking after the prior surge as well as investor recognition that the quarter's profit was largely a one-time, non-cash accounting result. Sentiment remains focused on the durability of the company's cash runway and the clinical path of its wholly owned pipeline rather than the headline earnings beat.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will likely shift their attention from the one-time revenue recognition toward Alector's long-term pipeline economics. The Genentech agreement provides $100 million in near-term capital plus up to an additional $1.17 billion in development, regulatory, and commercial milestones, along with tiered royalties — a substantial de-risking event for the AL050 program. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key catalysts include progress on AL137, the company's lead anti-amyloid beta antibody, as well as the AL164 tau program and AL062 alpha-synuclein program, which utilize small interfering RNA (siRNA) technology. Alector has targeted first-in-human subcutaneous dosing for one program in Australia no later than April 2027.
Investors should also monitor spending discipline, as reduced personnel and wind-down costs have helped narrow operating expenses. With management projecting a cash runway into the second half of 2029, the company's ability to advance its pipeline without additional near-term dilution will be a central theme in the quarters ahead.
Using Tickeron’s AI Screener for Deeper Analysis
In my own research process, Tickeron’s AI Screener helps me quickly filter biotech names by fundamentals, technical patterns, and recent performance. It is especially useful when sorting through earnings results like these to spot comparable companies or emerging trends without spending hours on manual screens. I have found it a practical addition to reviewing quarterly reports and pipeline updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALEC saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for ALEC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 64 similar instances where the indicator exited the overbought zone. In 60 of the 64 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ALEC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALEC entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ALEC as a result. In 79 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ALEC just turned positive on October 27, 2026. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
ALEC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +22.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 220 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.407) is normal, around the industry mean (2.788). P/E Ratio (-1.917) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders
Industry Biotechnology
Advertisement